Clinical use and pharmacological properties of selective COX-2 inhibitors.
about
Nonsteroidal Anti-Inflammatory Drugs and the KidneySynergistic analgesia of duloxetine and celecoxib in the mouse formalin test: a combination analysisRecovery from hematopoietic injury by modulating prostaglandin E(2) signaling post-irradiationPharmacokinetic-pharmacodynamic modelling of the analgesic effects of lumiracoxib, a selective inhibitor of cyclooxygenase-2, in rats.Comparison and validation of data-mining indices for signal detection: using the Korean national health insurance claims database.Cyclooxygenase-2-dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancerGuidelines for the Design and Conduct of Clinical Studies in Knee Articular Cartilage Repair: International Cartilage Repair Society Recommendations Based on Current Scientific Evidence and Standards of Clinical Care.Evidence of different mediators of central inflammation in dysfunctional and inflammatory pain--interleukin-8 in fibromyalgia and interleukin-1 β in rheumatoid arthritisCelecoxib Inhibits the Lytic Activation of Kaposi's Sarcoma-Associated Herpesvirus through Down-Regulation of RTA Expression by Inhibiting the Activation of p38 MAPK.PET imaging of cyclooxygenase-2 (COX-2) in a pre-clinical colorectal cancer model.A trifluoromethyl analogue of celecoxib exerts beneficial effects in neuroinflammation.Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles.Pharmacokinetics and drug metabolism in the elderly.Comparison of the Effect of Stretching Exercises and Mefenamic Acid on the Reduction of Pain and Menstruation Characteristics in Primary Dysmenorrhea: A Randomized Clinical Trial.Celecoxib enhances the radiosensitivity of HCT116 cells in a COX-2 independent manner by up-regulating BCCIP.Imaging COX-2 expression in cancer using PET/SPECT radioligands: current status and future directions.A Computational Method for Unveiling the Target Promiscuity of Pharmacologically Active Compounds.Celecoxib enhances radiosensitivity of hypoxic glioblastoma cells through endoplasmic reticulum stress.Concurrent targeting of eicosanoid receptor 1/eicosanoid receptor 4 receptors and COX-2 induces synergistic apoptosis in Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus associated non-Hodgkin lymphoma cell lines.Efficacy of celecoxib for acute pain management following total hip arthroplasty in elderly patients: A prospective, randomized, placebo-control trialInvolvement of PGE2 and RANTES in Staphylococcus aureus-induced fever in rats.Pre-emptive 8 mg dexamethasone and 120 mg etoricoxib for pain prevention after periodontal surgery: A randomised controlled clinical trialSustained-release celecoxib from incubated acrylic intraocular lenses suppresses lens epithelial cell growth in an ex vivo model of posterior capsule opacity.Preemptive dexamethasone and etoricoxib for pain and discomfort prevention after periodontal surgery: a double-masked, crossover, controlled clinical trial.Impact of chronic inflammation on the pharmacokinetic-pharmacodynamic relationship of naproxen.S-propargyl-cysteine (ZYZ-802), a sulphur-containing amino acid, attenuates beta-amyloid-induced cognitive deficits and pro-inflammatory response: involvement of ERK1/2 and NF-κB pathway in rats.Lumiracoxib metabolism in male C57bl/6J mice: characterisation of novel in vivo metabolites.Discovery of synthetic small molecules that enhance the number of stomata: C-H functionalization chemistry for plant biology.Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double-blind, placebo-controlled trial.The use of etoricoxib and celecoxib for pain prevention after periodontal surgery: a double-masked, parallel-group, placebo-controlled, randomized clinical trial.Synthesis of three 18F-labelled cyclooxygenase-2 (COX-2) inhibitors based on a pyrimidine scaffold.COX-2 is not required for the development of murine chronic pancreatitis
P2860
Q28386844-D1CE0B09-2F1E-4206-9C72-4913E6051EE3Q28534142-EB4CEA20-80FA-4B64-8B05-697070A0A33CQ33404654-F2066C11-20A5-435F-9CB8-70B78C252B26Q33661085-D59C34F6-A3F3-4D02-A089-943415833454Q34082600-368E60E9-70DC-4352-8894-A246A9F28945Q34128977-C396C1D4-D131-45E2-8BE3-E56D4B199AA8Q34991499-BBD25AA8-2870-469E-BB7F-AA7A794EC4E6Q35213524-29161664-C3EC-40A1-B75E-32842A13E302Q35675995-D1FFFD94-89C6-472F-AA75-8EB92F333711Q36834358-9207203C-D580-4ED9-8BAA-B94E7C849632Q37384508-FA1EE81E-A46E-4826-863E-413D5153B83FQ37415814-E20820C5-B5D5-44EE-9741-CCA6F35AC199Q37514319-6B7F2167-E463-4A9C-8BFE-C12AB62CB4E2Q37533196-19324502-03B0-44B0-BBDC-A3F32F45B283Q37732985-F2977174-59A3-4469-9638-78FBB510B0A3Q38182495-960D5C9E-FEC6-43C9-9C85-49F1B9CC33D9Q38658125-CC431B91-4F3A-4827-8C79-0529794BC600Q39154529-8A42490E-17F2-46D3-AE67-DCC2CDC48104Q39176686-950E5894-098B-42BB-9825-0C71F6E52FF8Q39180018-72DEAC5A-CC26-4EFA-BF98-EA725FEEB9BDQ40275859-A1F08E0C-9677-4038-9BFE-1C0172839A40Q41760559-8CEC228D-A517-4114-82EA-BF2ECEEC1E6EQ42059809-7E5B0A28-FC97-4C65-98FF-145098E98B90Q43109525-4F06995E-7807-44C4-8DC5-C4A704CEF616Q43292343-AB009942-DF17-42CC-BBB3-4EC385E79B16Q44301714-FD7ED6F1-8AF6-4271-9C85-6A2F86E6FA7DQ46514701-8C003A68-5E6F-4424-A897-5A67E39E82FBQ47927443-9E665FCF-5745-431D-BC8D-24B21BC7ACEBQ48075396-2B19BF6A-E7E5-4FBF-9B5D-DEC6D0E51DD8Q50648569-8557AB88-31EC-4DA1-9008-42A97B749715Q54717485-1A9A9790-8D49-453A-BD25-BAD3BCA988C7Q57546918-7610B9F7-0C3D-4A58-AE4B-FC5E2CBCAF7C
P2860
Clinical use and pharmacological properties of selective COX-2 inhibitors.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Clinical use and pharmacological properties of selective COX-2 inhibitors.
@ast
Clinical use and pharmacological properties of selective COX-2 inhibitors.
@en
Clinical use and pharmacological properties of selective COX-2 inhibitors.
@nl
type
label
Clinical use and pharmacological properties of selective COX-2 inhibitors.
@ast
Clinical use and pharmacological properties of selective COX-2 inhibitors.
@en
Clinical use and pharmacological properties of selective COX-2 inhibitors.
@nl
prefLabel
Clinical use and pharmacological properties of selective COX-2 inhibitors.
@ast
Clinical use and pharmacological properties of selective COX-2 inhibitors.
@en
Clinical use and pharmacological properties of selective COX-2 inhibitors.
@nl
P2860
P1476
Clinical use and pharmacological properties of selective COX-2 inhibitors.
@en
P2093
Shaojun Shi
Ulrich Klotz
P2860
P2888
P304
P356
10.1007/S00228-007-0400-7
P577
2007-11-13T00:00:00Z
P6179
1030230454